Key result
In patients with ischemic heart disease, an unfavorable 12-month course of chronic heart failure was associated with lower baseline serum VEGF levels.
Why the study?
Do serum levels of VEGF, PDGF-AB, and FGF-basic correlate with the severity and prognosis of chronic heart failure in patients with ischemic heart disease?
Cohort (n=126)
Yes
Do serum levels of VEGF, PDGF-AB, and FGF-basic correlate with the severity and prognosis of chronic heart failure in patients with ischemic heart disease?
Answers are grounded in this paper and cite their sources.
Serum levels of VEGF, PDGF-AB, and FGF-basic serve as potential biomarkers for the severity and 12-month prognosis of chronic heart failure in patients with ischemic heart disease.
AIM: To study the role of growth factors ((vascular endothelial growth factor (VEGF), platelet derived growth factor AB (PDGF-AB) and basic fibroblast growth factor (FGF-basic)) in the development and progression of chronic heart failure (CHF) in patients with ishcemic heart disease (IHD). MATERIALS AND METHODS: We included in this study 94 patients with CHF. The control group comprised 32 persons. Blood serum levels of growth factors were determined at baseline and after 12 months of observation by enzyme-linked immunosorbent assay. RESULTS: VEGF, PDGF-AB and FGF-basic play an important role in the pathogenesis and progression of heart failure in patients with IHD, determining the increased risk of adverse cardiovascular events in this pathology. Serum activity of growth factors characterizes the severity and course of CHF: with disease progression levels of VEGF and FGF-basic decrease and PDGF-AB concentration increases. Initial low level of VEGF expression regardless of the sex of the patient's sex, significantly low level of FGF-basic and significantly high PDGF-AB in men characterizes unfavorable course of CHF. CONCLUSION: A correlation has been established between blood serum levels of VEGF, PDGF-AB and FGF-basic and severity and course of CHF.
No takes yet. Share an insight, caveat, or question.
Teplyakov et al. (2017) conducted a cohort in Chronic heart failure (n=126). Serum growth factors (VEGF, PDGF-AB, FGF-basic) vs. Favorable clinical course was evaluated on Baseline serum VEGF levels (pg/ml) in men with unfavorable vs favorable 12-month course of chronic heart failure (p=0.0076). In patients with ischemic heart disease, an unfavorable 12-month course of chronic heart failure was associated with lower baseline serum VEGF levels.
Synapse has enriched 10 related papers. Consider them for comparative context: